Summer School in Translational Cancer Research, October 8 – 14, 2023, Portugal

The CCE Summer School in Translational Cancer Research is intended to provide an in-depth training of scientists and clinicians to gain a cross-disciplinary knowledge of areas of the entire cancer research continuum.

The Summer School covers a broad spectrum of topics ranging from preclinical and clinical research to the implementation of scientific insights into the health care system. An important goal of the Summer School is the interaction between participants as well as speakers, coming from both preclinical laboratories and clinical centers worldwide. We aim at stimulating interactions to foster multidisciplinary collaborations at an international level. Participants have the opportunity to present their research projects and data in oral or poster presentations.

How to apply

Registration is no longer available. Thank you for your interest

Applicants need to complete an online form (available mid-April 2023) including the submission of a scientific abstract. The Scientific Committee will evaluate all complete applications. Once, the evaluation is finalized, the Organising Team will inform the applicants about the status of their applications. Participation in the Summer School requires a poster presentation and/or – if selected – a talk.

We are looking forward to your application!

PhD students, postdocs and researching clinicians with an interest in translational cancer research.

Cost contribution (1,000.00 €) covers:

  • Five-days scientific program
  • Accommodation for six nights (Sunday, October 8 – Saturday, October 14, 2023) at double room occupancy (shared rooms are same-gender rooms).Requests for a single room will be considered, are subject to availability and will be charged at an additional cost. Similarly, personal expenses such as bar tabs, mini bar, telephone, etc. are not included in the package. Any such costs shall be at the participant’s expense.
  • Full board (starting with dinner on Sunday, October 8 and finishing with breakfast on Saturday, October 14, 2023).
  • Shuttle service from Faro airport or Albufeira train station to the hotel and back upon request.
  • Abstract book
  • Certificate of attendance

Payment details, as well as our cancellation policy, will be provided with the acceptance information

Only very few scholarships covering the participation fee can be granted. Please be aware that if you wish to apply for a scholarship, you will be asked to provide the following information during the application process:

  • A brief explanation of why your institute cannot provide the necessary funding (max. 200 words).
  • One reference letter.

As the fellowships will be very competitive and limited in number, we strongly advise checking for additional internal or external funding opportunities.

If needed, the Organising Team will provide you with a visa letter. Please request the letter as soon as possible after paying the cost contribution.

Main topics for the Summer School

Confirmed Speakers

  • Jürgen Becker, German Cancer Consortium (DKTK), University of Duisburg-Essen, Germany

  • Richard Baird, Cancer Research UK Cambridge Centre, University of Cambridge, UK
  • Benjamin Besse, Gustave Roussy, France
  • Irene Braña, Vall d’Hebron Institute of Oncology, Spain
  • Filippo de Braud, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy
  • Priya Chudasama, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Consortium (DKTK), Germany
  • Mireia Crispin Ortuzar, Cancer Research UK Cambridge Centre, University of Cambridge, UK
  • Karim Fizazi, Gustave Roussy, University of Paris-Saclay, France
  • Stefan Fröhling, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Consortium (DKTK), Germany
  • Florent Ginhoux, Gustave Roussy, France
  • Hugo Horlings, Netherlands Cancer Institute, The Netherlands
  • Ellen Kampman, Wageningen University, The Netherlands
  • Bruno Köhler, University Hospital Heidelberg, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Consortium (DKTK), Germany
  • Marleen Kok, Netherlands Cancer Institute, The Netherlands
  • Svetlana Bajalica Lagercrantz, Karolinska Institutet, Karolinska University Hospital, Sweden
  • Janne Lehtiö, Karolinska Institutet, Sweden

  • Thomas Mercher, INSERM U1170, Gustave Roussy Cancer Center, Université Paris Saclay, France

  • Daniel Mertens, Trainer for transferable skills, Schiller & Mertens, Germany
  • Delia Mezzanzanica, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy

  • Tamara Milagre, Patient Association EVITA, Portugal
  • Raquel Pérez-López, Vall d’Hebron Institute of Oncology (VHIO), Spain
  • Stefan Pfister, German Cancer Research Center (DKFZ), University Hospital Heidelberg, Hopp Children’s Cancer Center Heidelberg (KiTZ), German Cancer Consortium (DKTK), Germany
  • Lucia Sfondrini, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy
  • Josep Tabernero, Vall d’Hebron Institute of Oncology (VHIO), Spain and Chair of the CCE (from October2023)
  • Maria-Veronica Teleanu, German Cancer Research Center (DKFZ), University Hospital Heidelberg, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Consortium (DKTK), Germany
  • Nick Tobin, Karolinska Institutet, Sweden and Chair of the Scientific committee
  • Emile Voest, Netherlands Cancer Institute and The Oncode Institute, The Netherlands and chair of CCE (until October 2023)
  • Lisa Westerberg, Karolinska Institutet, Sweden
  • Margareta Wilhelm, Karolinska Institutet, Sweden

Location

For one week, participants will stay at the beautiful PortoBay Falésia, in the Algarve, Portugal. This will provide a unique opportunity to work closely with the experts, meet new people in the field and interact to foster multidisciplinary collaborations at an international level. Participants have the opportunity to present their research projects and data in oral or poster presentations.

Join us to improve your skills and broaden your network!

Accommodation (twin room) and full board for 6 days starting from Sunday October 8, 2023 (arrival day) to Saturday October 14, 2023 (departure day) is included in the Summer School registration fee. For any further arrangements (e.g. single rooms, accompanying persons) please contact us: summerschool@cancercoreeurope.eu.

A shuttle service from/to Faro airport / train station or Albufeira train station to the hotel is included in the Summer School registration fee and available upon request. Please use the reservation link included in your confirmation e-mail to sign up for the shuttle service

VENUE

Hotel PortoBay Falésia
Quinta do Milharó, Olhos de Água
8200-591 Albufeira – Portugal

WHAT OUR PARTICIPANTS SAY

Prince A., India: “The heterogeneity of the crowd is really where you get to know more and more people from different parts of the world, and what they are doing in the clinical setting, as well as in the labs. Different activities – just like a walk on a beach or soccer on a beach helps you to get to know more and more people and it helps you to mingle with the people of your own research interest.“

Tania C., Germany: “What I enjoyed most so far is really that you interact with many different people from different disciplines and also different career levels. You can actually get a lot of inspiration on your own projects.“
Gunn A., Denmark: “I would like to say thank you for an absolute fantastic week in Portugal! I have never experienced a more successful event, both socially and professionally!”
Rihan E. B., Italy: “Especially in this very challenging war against cancer, we really need to stand together, because the whole is greater than the sum of its parts, so we need to be a core against cancer. And this is definitely what I found here in Cancer Core Europe.“
Omnia E., Egypt: “I like the diversity here, and the creativity, and how everyone gets to interact based on his own background.“

Andreas M., Germany: “Summer School brings people together, it creates opportunity, it gives us an important stimulus, and really fosters collaboration between young researchers.“

SCIENTIFIC COMMITTEE

Dr. Nick Tobin
Karolinska Institutet (KI)
Stockholm, Sweden

Dr. Irene Braña
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Dr. Richard Baird
Cancer Research UK Cambridge Centre
Cambridge, United Kingdom

Prof. Svetlana Bajalica Lagercrantz
Karolinska Institutet (KI)
Stockholm, Sweden

Prof. Ingemar Ernberg
Karolinska Institutet (KI)
Stockholm, Sweden

Dr. Marleen Kok
The Netherlands Cancer Institute (NKI)
Amsterdam, The Netherlands

Prof. Stefan Fröhling,
National Center for Tumor Diseases (NCT) – DKFZ
Heidelberg, Germany

Dr. Priya Chudasama,
National Center for Tumor Diseases (NCT) – DKFZ
Heidelberg, Germany

Dr. Delia Mezzanzanica,
Istituto Nazionale dei Tumori di Milano (INT)
Milan, Italy

Dr. Thomas Mercher,
Institut Gustave Roussy (IGR)
Villejuif, France

Dr. Mate Maus
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

ORGANISERS

   An alliance of 7 leading European cancer centers

SUPPORTERS

The German Cancer Consortium (DKTK) is a long-term, joint initiative involving the German Federal Ministry of Education and Research (BMBF), participating German states and the German Cancer Research Center (DKFZ) and was established as one of six German Health Research Centres (DZGs) in 2012. The German Cancer Research Center, the consortium’s core center, works together with more than 20 academic research institutions and university hospitals in Berlin, Dresden, Essen/Düsseldorf, Frankfurt/Mainz, Freiburg, Munich and Tübingen to create the best possible conditions for preclinical-translational cancer research. The consortium promotes interdisciplinary research at the interface between basic research and clinical research. Another key focus of the consortium’s work is on developing research platforms to speed up the application of personalized cancer treatments and to improve the diagnosis and prevention of cancer.

The mission of Cancer Prevention Europe (CPE), a consortium of organizations across the whole of Europe, is to reduce morbidity and mortality from cancer in European populations through prevention and earlier detection of the disease. This will be accomplished through (1) research to optimize the implementation of known preventive strategies, (2) the dissemination of established best practices in prevention, in order to see innovative research translated into effective cancer prevention guidelines and policies nationally and internationally, and (3) research to identify novel targets for prevention.

Molecular Oncology is an open access journal owned by FEBS. The journal considers Research Articles from the fields of basic, translational, and clinical cancer research. We also publish Review Articles, Commentaries and Policy Papers discussing emerging concepts in cancer research, cancer diagnosis, prevention and care. Journal profits are re-invested in the scientific community. Manuscripts are handled by a team of dedicated academic Section Editors under a transparent peer review scheme.

Algarve Biomedical Center has as its main mission the creation, transmission and dissemination of a culture of research and development, helping the training of highly qualified and differentiated professionals. ABC’s vision is to be a center of excellence dedicated to development, training and research, based on the pillars of efficiency, quality, competitiveness and innovation.

EMBO is an organization of more than 2,000 leading researchers that promotes excellence in the life sciences in Europe and beyond. The major goals of the organization are to support talented researchers at all stages of their careers, stimulate the exchange of scientific information, and help build a research environment where scientists can achieve their best work.

NOVARTIS is reimagining medicine to improve and extend people’s lives. We deliver high-value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. About 108,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.

ORGANISING TEAM

Petra Oberrauch,
National Center for Tumor Diseases (NCT) – DKFZ
Heidelberg, Germany

Thomas Guegan,
VHIO Academy (VHIO)
Barcelona, Spain

Natalia Molner,
VHIO Academy (VHIO)
Barcelona, Spain

Giovanni Scoazec,
Istituto Nazionale dei Tumori di Milano (INT)
Milan, Italy

Natalia Czerniak,

VHIO Academy (VHIO)

Barcelona, Spain

You can contact us at: summerschool@cancercoreeurope.eu

Financial aspects of the Summer School are managed by Gustave Roussy: cce@gustaveroussy.fr